上皮成長因子受容体(EGFR)阻害剤の世界市場2019-2023

◆英語タイトル:Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023
◆商品コード:IRTNTR31465
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月19日
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、上皮成長因子受容体(EGFR)阻害剤の世界市場について調べ、上皮成長因子受容体(EGFR)阻害剤の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、上皮成長因子受容体(EGFR)阻害剤の市場規模をセグメンテーション別(疾患別(肺がん、結腸直腸がん、乳がん、その他))と地域別(グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米)に分けて算出しました。
・サマリー
・レポートの範囲
・上皮成長因子受容体(EGFR)阻害剤の市場状況
・上皮成長因子受容体(EGFR)阻害剤の市場規模
・上皮成長因子受容体(EGFR)阻害剤の市場予測
・上皮成長因子受容体(EGFR)阻害剤の世界環境:ファイブフォース分析
・市場セグメンテーション:疾患別(肺がん、結腸直腸がん、乳がん、その他)
・上皮成長因子受容体(EGFR)阻害剤の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: About this market

The epidermal growth factor receptor (EGFR) is a protein-coding gene. It is found in high levels on cancer cells and is known to be responsible for the uncontrolled cell growth Inhibiting or blocking the growth of EGFR can stop the growth of cancer cells for long durations of time. Technavio’s epidermal growth factor receptor inhibitors market analysis considers the revenue based on indications such as lung cancer, colorectal cancer, breast cancer, and others. Our analysis also finds the sales of the epidermal growth factor receptor inhibitors in North America, Europe, Asia, and ROW. In 2018, lung cancer had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the substantial prevalence of the disease will play a vital role in the lung cancer segment to maintain its market position. Also, our global epidermal growth factor receptor inhibitors market report looks at factors such as the substantial prevalence of major cancer indications, increasing awareness campaigns, and research funding. However, the high treatment costs, high preference for alternative therapies, and patent cliff may hamper the growth of the epidermal growth factor receptor inhibitors industry over the forecast period.

Global epidermal growth factor receptor inhibitors market: Overview

Strong prevalence of major cancer indications

The prevalence of various types of cancers has increased at a significant rate in recent years, owing to increasing geriatric population and changing lifestyle. The market is witnessing the vast unmet need for novel therapies for the treatment of cancer indications. This is creating huge opportunities for vendors to conduct studies on drugs such as EGFR inhibitors for the treatment of cancer. Thus, the substantial prevalence of major cancer indications will lead to the growth of the global EGFR inhibitors market at a CAGR of almost 9% during the forecast period.

New research areas

EGFR inhibitors are considered to be highly effective for the treatment of various types of cancer indications, which is encouraging researchers to study its use in the treatment of inflammatory and monogenic diseases. Hence, the new research areas of EGFR inhibitors are identified as a critical trend that will have a positive impact on the growth of the EGFR inhibitors market during the forecast period.

For the detailed list of factors that will drive the global epidermal growth factor receptor inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few significant players, the global epidermal growth factor receptor inhibitors market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor inhibitors manufacturers, that include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Novartis AG.

Also, the epidermal growth factor receptor inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY INDICATION

Market segmentation by indication

Comparison by indication

Lung cancer – Market size and forecast 2018-2023

Colorectal cancer – Market size and forecast 2018-2023

Breast cancer – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by indication

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

AstraZeneca Plc

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Novartis AG

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01:Global pharmaceuticals market

Exhibit 02:Segments of global pharmaceuticals market

Exhibit 03:Market characteristics

Exhibit 04:Market segments

Exhibit 05:Market definition – Inclusions and exclusions checklist

Exhibit 06:Market size 2018

Exhibit 07:Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08:Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09:Five forces analysis 2018

Exhibit 10:Five forces analysis 2023

Exhibit 11:Bargaining power of buyers

Exhibit 12:Bargaining power of suppliers

Exhibit 13:Threat of new entrants

Exhibit 14:Threat of substitutes

Exhibit 15:Threat of rivalry

Exhibit 16:Market condition – Five forces 2018

Exhibit 17:Indication – Market share 2018-2023 (%)

Exhibit 18:Comparison by indication

Exhibit 19:Lung cancer – Market size and forecast 2018-2023 ($ millions)

Exhibit 20:Lung cancer – Year-over-year growth 2019-2023 (%)

Exhibit 21:Colorectal cancer – Market size and forecast 2018-2023 ($ millions)

Exhibit 22:Colorectal cancer – Year-over-year growth 2019-2023 (%)

Exhibit 23:Breast cancer – Market size and forecast 2018-2023 ($ millions)

Exhibit 24:Breast cancer – Year-over-year growth 2019-2023 (%)

Exhibit 25:Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 26:Estimated number of new cancer cases and deaths in the US – 2019

Exhibit 27:Others – Year-over-year growth 2019-2023 (%)

Exhibit 28:Market opportunity by indication

Exhibit 29:Customer landscape

Exhibit 30:Market share by geography 2018-2023 (%)

Exhibit 31:Geographic comparison

Exhibit 32:North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33:North America – Year-over-year growth 2019-2023 (%)

Exhibit 34:Top 3 countries in North America

Exhibit 35:Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36:Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37:Top 3 countries in Europe

Exhibit 38:Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39:Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40:Top 3 countries in Asia

Exhibit 41:ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42:ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43:Top 3 countries in ROW

Exhibit 44:Key leading countries

Exhibit 45:Market opportunity

Exhibit 46:Estimated new cancer cases and deaths in US 2019

Exhibit 47:Organizations conducting awareness campaigns

Exhibit 48:Impact of drivers and challenges

Exhibit 49:Global EGFR inhibitors market: pipeline

Exhibit 50:Vendor landscape

Exhibit 51:Landscape disruption

Exhibit 52:Vendors covered

Exhibit 53:Vendor classification

Exhibit 54:Market positioning of vendors

Exhibit 55:Amgen Inc. – Vendor overview

Exhibit 56:Amgen Inc. – Business segments

Exhibit 57:Amgen Inc. – Organizational developments

Exhibit 58:Amgen Inc. – Geographic focus

Exhibit 59:Amgen Inc. – Key offerings

Exhibit 60:Amgen Inc. – Key customers

Exhibit 61:AstraZeneca Plc – Vendor overview

Exhibit 62:AstraZeneca Plc – Business segments

Exhibit 63:AstraZeneca Plc – Organizational developments

Exhibit 64:AstraZeneca Plc – Geographic focus

Exhibit 65:AstraZeneca Plc – Key offerings

Exhibit 66:AstraZeneca Plc – Key customers

Exhibit 67:Eli Lilly and Co. – Vendor overview

Exhibit 68:Eli Lilly and Co. – Business segments

Exhibit 69:Eli Lilly and Co. – Organizational developments

Exhibit 70:Eli Lilly and Co. – Geographic focus

Exhibit 71:Eli Lilly and Co. – Segment focus

Exhibit 72:Eli Lilly and Co. – Key offerings

Exhibit 73:Eli Lilly and Co. – Key customers

Exhibit 74:F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 75:F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 76:F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 77:F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 78:F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 79:F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 80:F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 81:Novartis AG – Vendor overview

Exhibit 82:Novartis AG – Business segments

Exhibit 83:Novartis AG – Organizational developments

Exhibit 84:Novartis AG – Geographic focus

Exhibit 85:Novartis AG – Segment focus

Exhibit 86:Novartis AG – Key offerings

Exhibit 87:Novartis AG – Key customers

Exhibit 88:Validation techniques employed for market sizing

Exhibit 89:Definition of market positioning of vendors



【掲載企業】

Amgen Inc.、AstraZeneca Plc、Eli Lilly and Co.、F. Hoffmann-La Roche Ltd.、Novartis AG

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[上皮成長因子受容体(EGFR)阻害剤の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆